• 1. Distinct correlation between (CN2)x units and pores: a low-cost method for predesigned wide range control of micropore size of porous carbon?
  Xiaotong Feng,Lei Bian,Jie Ma,Lei Zhou,Xiayan Wang,Guangsheng Guo,Qiaosheng Pu Chem. Commun., 2019,55, 3963-3966
• 2. Excitation energies from ground-state density-functionals by means of generator coordinates
  A. B. F. da Silva,K. Capelle Phys. Chem. Chem. Phys., 2009,11, 4564-4569
• 3. Evidence of rutile-to-anatase photo-induced electron transfer in mixed-phase TiO2 by solid-state NMR spectroscopy?
  Weili Dai,Guangjun Wu,Michael Hunger Chem. Commun., 2015,51, 13779-13782
• 4. Emerging 2D hybrid nanomaterials: towards enhanced sensitive and selective conductometric gas sensors at room temperature
  Hanie Hashtroudi,Ian D. R. Mackinnon J. Mater. Chem. C, 2020,8, 13108-13126
• 5. Evidence of field induced slow magnetic relaxation in cis-[Co(hfac)2(H2O)2] exhibiting tri-axial anisotropy with a negative axial component?
  Denis V. Korchagin,Elena A. Yureva,Alexander V. Akimov,Eugenii Ya. Misochko,Gennady V. Shilov,Artem D. Talantsev,Roman B. Morgunov,Alexander A. Shakin,Sergey M. Aldoshin,Boris S. Tsukerblat Dalton Trans., 2017,46, 7540-7548

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazinanes Piperazines

Recent Advances in the Study of (R)-2-Hydroxymethyl-piperazine (CAS: 149715-47-9) in Chemical Biology and Pharmaceutical Research

(R)-2-Hydroxymethyl-piperazine (CAS: 149715-47-9) is a chiral piperazine derivative that has garnered significant attention in the field of chemical biology and pharmaceutical research due to its versatile applications in drug design and synthesis. Recent studies have highlighted its potential as a key building block for the development of novel therapeutic agents, particularly in the areas of central nervous system (CNS) disorders, oncology, and infectious diseases. This research brief aims to provide an overview of the latest findings related to this compound, focusing on its synthesis, biological activity, and therapeutic applications.

One of the most notable advancements in the study of (R)-2-Hydroxymethyl-piperazine is its role as a chiral auxiliary in asymmetric synthesis. Researchers have successfully employed this compound to achieve high enantioselectivity in the synthesis of complex molecules, including protease inhibitors and kinase modulators. For instance, a recent study published in the Journal of Medicinal Chemistry demonstrated the use of (R)-2-Hydroxymethyl-piperazine as a scaffold for the development of selective inhibitors of the enzyme dipeptidyl peptidase-4 (DPP-4), which is a target for type 2 diabetes treatment. The study reported improved pharmacokinetic properties and enhanced binding affinity compared to previous analogs.

In addition to its synthetic utility, (R)-2-Hydroxymethyl-piperazine has shown promising biological activity in preclinical models. A 2023 study in Bioorganic & Medicinal Chemistry Letters explored its potential as an anti-cancer agent, revealing that derivatives of this compound exhibited potent inhibitory effects on the proliferation of certain cancer cell lines, including breast and lung cancer. The mechanism of action was attributed to the modulation of key signaling pathways involved in cell cycle regulation and apoptosis. These findings suggest that (R)-2-Hydroxymethyl-piperazine-based compounds could serve as a foundation for the development of new anti-cancer therapies.

Another area of interest is the application of (R)-2-Hydroxymethyl-piperazine in the design of CNS-targeted drugs. Recent research has demonstrated its efficacy in enhancing blood-brain barrier (BBB) penetration, a critical factor for the treatment of neurological disorders. A study published in ACS Chemical Neuroscience reported that (R)-2-Hydroxymethyl-piperazine derivatives exhibited improved BBB permeability and reduced off-target effects, making them suitable candidates for the treatment of Alzheimer's disease and Parkinson's disease. The study also highlighted the compound's ability to modulate neurotransmitter systems, further underscoring its therapeutic potential.

Despite these promising developments, challenges remain in the optimization of (R)-2-Hydroxymethyl-piperazine-based compounds for clinical use. Issues such as metabolic stability, toxicity, and scalability of synthesis need to be addressed in future research. However, the growing body of evidence supports the continued exploration of this compound as a valuable tool in drug discovery and development. Ongoing studies are expected to uncover new applications and refine existing methodologies, paving the way for innovative therapeutic solutions.

In conclusion, (R)-2-Hydroxymethyl-piperazine (CAS: 149715-47-9) represents a versatile and promising compound in the field of chemical biology and pharmaceutical research. Its applications in asymmetric synthesis, anti-cancer therapy, and CNS drug development highlight its broad utility and potential for future breakthroughs. As research progresses, this compound is likely to play an increasingly important role in the discovery of next-generation therapeutics.

• 98275-69-5(2-Piperazinemethanol,5-methyl-)
• 141108-61-4((1-Methylpiperazin-2-yl)methanol)
• 155225-18-6(2-Piperazinemethanol,4-methyl-, (2S)-)
• 173966-31-9(2-Piperazinemethanol,4-methyl-,(R)-(9CI))
• 28795-50-8((piperazin-2-yl)methanol)
• 14675-44-6((1,4-Dimethylpiperazin-2-yl)methanol)
• 90796-58-0(2-Piperazinemethanol,1,4-diethyl-)
• 126872-94-4((2S)-2-Piperazinemethanol)
• 122323-87-9(Piperazin-2-ylmethanol dihydrochloride)
• 149629-73-2((S)-Piperazin-2-ylmethanol dihydrochloride)